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Abstract
Background: We carried out a three months follow-up study on the efficacy of metadoxine in a
cohort of alcoholics admitted to the Alcohol misuse Long-term Treatment (ALT) Unit – University
of Pisa (Italy). We analyzed the clinical data, psychometric tests and blood tests of 160 alcoholics
on admission and after 3 months of treatment. We compared 58 pts treated with metadoxine
(MET) with 102 pts who did not receive (NULL) any drug as an adjunct to the psycho-educational
interventions provided by the ALT Unit.
Results:  At follow-up, the patients in treatment with metadoxine showed a significant
improvement in the rate of complete abstinence (44.8% vs. 21.6%; chi square: 8.45, df = 1, p <
0.0037). Furthermore, the number of drop-outs at three months of treatment was also significantly
lower in the MET than in the NULL group (17% vs. 57%; chi square of 23.22, df = 1, p < 0.001).
Conclusion:  Our findings support the use of metadoxine in the management of alcohol
dependence. However, randomized clinical trials are necessary to confirm and replicate them. This
study raises the importance of identifying new pharmacological compounds effective on the
outcome of alcoholism in order to help patients to best adhere to treatment programs and to
prevent the development of mental and physical complications due to chronic and heavy use of
alcohol.
Background
Alcohol misuse is a common problem in the general pop-
ulation all over the world. Recent surveys reported that
alcoholism affects almost 10–15% of the general popula-
tion in US and 1–5% in Europe [1-5]. There is a general
agreement in the scientific community that heavy drink-
ing is largely underestimated by clinicians and that alco-
hol misusers are often not detected unless and until they
develop severe alcohol related pathologies [6,7]. Accord-
ing to Stickel and co-workers (2003) in Europe more than
45 million individuals showed signs of alcohol-related
damage, mainly cognitive deficits, liver disease, and
myopathies [8-11]. The importance of the nutritional sta-
tus in the development of alcohol-related organ damage
has been postulated by several authors [8,12,13].
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A reduction in the blood levels of micro and macronutri-
ents, mainly B-complex vitamins, can impair the cognitive
functions and therefore compromise the recovery of alco-
holics [14]. In order to prevent brain damage and conse-
quential cognitive impairment, the guidelines for the
Accident & Emergency departments in United Kingdom
recommend the use of parenteral B vitamins for patients
showing evidence of chronic alcohol misuse and sus-
pected of having a poor diet [15]. The B-complex vitamins
(i.e. thiamine, pyridoxine etc) are extremely important for
the homeostasis of the brain, being key factors in the cell
metabolism and trafficking, in the energy production
pathways and in the DNA synthesis [16].
Therefore, it is important in the treatment of alcohol mis-
use to consider an integrated approach that includes phar-
macological and psychological intervention, social
support and nutritional supplementation.
Several studies have proposed the use of metadoxine in
the treatment of acute and chronic alcohol misusers [17-
21]. Metadoxine is an ion-pair between pyrrolidon car-
boxilate (PCA) and pyridoxine (vit. B6) with the two com-
pounds linked in a single product by salification. This
process synergistically increases its pharmacological activ-
ity [17]. In animal studies metadoxine increases the
plasma and urinary excretion of ethanol, inhibits the
increased production of fatty acid esters in the liver during
chronic alcohol intake, reduces oxidative stress and pre-
vents glutathione depletion in the hepatic tissues [17]. In
the brain metadoxine increases the level of GABA and ace-
tylcholine in the frontoparietal cortex of guinea pigs [22].
In mice it increases the level of dopamine in the stria-
tum[23,24].
In human studies, it has also been postulated that meta-
doxine is effective in maintaining abstinence, in decreas-
ing the craving for alcohol and in improving the cognitive
function mainly short-term memory [17,19,20]. The
improvement of the short-term memory can be related to
the effect of this compound on the cholinergic and
gabaergic system reported by Antonelli and coworkers in
guinea pigs [22].
Clinical trials showed that in acutely intoxicated patients
metadoxine reduces the ethanol blood levels and
increases the urinary clearance of ethanol and its metabo-
lites [21]. Metadoxine seems to be effective in the recovery
of fatty liver and in improving the laboratory blood tests
[18] and, as shown by Shpilenya and coworkers (2002), it
seems to ameliorate the clinical and behavioural symp-
toms during alcohol intoxication [21]. Caballeria and co-
workers (1998) reported in a double-blind randomized
multicentre study that metadoxine significantly improves
the liver enzymes and reduces the rate of steatosis after
just a month of treatment [18].
We carried out a follow-up study on the efficacy of meta-
doxine in a cohort of alcoholics admitted to the Alcohol
misuse Long-term Treatment (ALT) Unit at the Institute of
Psychiatry University of Pisa (Italy). The purpose of this
study is to test the potential benefits of using metadoxine
in the management of Alcohol Dependence.
Results
The 160 patients were 134 males and 26 females (mean
age 44 yrs; SD = 11.) At admission at ALT Unit all the
patients were completely detoxified and totally abstinent
from alcohol. The fifty-eight patients in treatment with
metadoxine received a daily dose of metadoxine of 1000
mg, orally administered three times a day.
The clinical characteristics of the samples are shown in
Table 1. The alcohol intake refers to the amount con-
sumed before admission to the ALT Unit. The intake is cal-
culated in grams of alcohol according to Italian standards
(see Guerrini et al., 2006 as a reference)[5]. The Family
History (FH) for Alcohol Dependence was evaluated by
two independent clinicians, interviewing the patient and
one of his/her first degree relatives. The Age of onset refers
to the age in which the individuals started having signs/
symptoms of Alcohol Dependence.
Table 2 shows the mean scores of the rating scales at
admission and after three months of treatment and the
analysis of the covariance. Only the MAST score was sig-
nificantly changed between the admission and the follow
up evaluation (One-way ANCOVA, F = 9.76, df = 1, df
error = 9, p < 0.01).
Table 3 shows the means and ANCOVA analysis of the
blood tests of the two groups (MET and NULL) at admis-
sion and at three months follow-up.
In terms of compliance, the cases in the MET group
showed a significantly lower number of dropouts com-
pared to the NULL group (17% vs. 57%; chi square of
23.22, df = 1, p < 0.001), data shown in Table 4.
Furthermore, the group treated with metadoxine showed
a better outcome in terms of complete abstinence after
three months of treatment (44.8% vs. 21.6%; chi square:
8.45, df = 1, p < 0.0037), data showed in Table 4.
Conclusion
The efficacy of metadoxine in the management of alcohol-
ism has been postulated by several authors [17,19-21].
The use of this compound has been analysed in several
pathological conditions from the acute alcohol intoxica-Substance Abuse Treatment, Prevention, and Policy 2006, 1:35 http://www.substanceabusepolicy.com/content/1/1/35
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tion to the liver pathology in chronic alcoholism [17] but
very few follow-up studies explored its role in the medium
and long-term treatment of Alcohol Dependence. Our fol-
low-up study covered a period of only three months and
was biased by the fact that the cases were not assigned
completely at random to each experimental condition.
Our findings indicate that the group of patients treated
with metadoxine shows a better three months outcome
both in terms of drop-out rate and complete abstinence.
These results are in accordance to the data reported by
Rizzo and co-workers (1993) that showed a better
improvement of the patients treated with metadoxine in
terms of abstinence maintenance at least in the short term
[19].
Regarding the psychometric rating scales score for alco-
holism only the MAST test showed a statistically different
improvement in the metadoxine treated group suggesting
a global improvement of the Alcohol Dependence.
All these findings suggest a possible effect of the metadox-
ine on the central nervous system. Several animal studies
postulate the role of this compound in the dopamine
release and in the GABA pathway. An anti-craving effect
has been suggested to explain the ability of this com-
pound to induce alcohol abstinence and to improve clin-
ical symptoms [17].
Both the pyrrolidon carboxilate (PCA) and the pyridoxol
are also important molecules involved in the energy
metabolism and in maintaining the homeostasis of the
brain. Wei et coworkers (1999) showed that serious cog-
nitive deficit occurs in vitamin B(6)-deficient animals
[25]. Nutritional deficiency is an important element in the
pathogenesis of cognitive impairment and consequently
affects the patients' compliance to the treatment. Further-
more PCA has been shown to have antioxidant effects and
seems to reduce the aging process in the brain [26]. Our
study suggests the importance of evaluating the role of
compounds such as micro and macronutrients (piridox-
ine, thiamine, folic acid, magnesium etc) in the treatment
of alcohol misuse. For example, the role of thiamine in
the prevention of cognitive deficits and severe brain dam-
age in alcoholics is well accepted by the scientific commu-
nity. Pharmacological compounds that show an effect on
the rate of complete abstinence are of extreme importance
in the treatment of alcohol dependence, a chronic relaps-
Table 2: Mean values of the rating scales according to treatment and time points and ANCOVA p-values. SD = Standard Deviation.
MET NULL ANCOVA analysis(*)
Baseline Follow-up Baseline Follow-up
MALT1 14 (SD:5) 8 (SD:7) 12 (SD:5) 12 (SD:11) P < 0.579
MALT2 16 (SD:5) 10 (SD:8) 14 (SD:5) 11 (SD:8) P < 0.08
MAST 25 (SD:8) 18 (SD:2) 18 (SD:1) 14 (SD:11) P < 0.01
HRSA 10 (SD:7) 8 (SD:8) 13 (SD:9) 7 (SD:7) P < 0.8
HRSD 10 (SD:6) 7 (SD:7) 12 (SD:7) 9 (SD:8) P < 0.47
(*) Note: p-values are from an F-test with 1, 9 df.
Table 1: Clinical characteristics of the patients recruited in the study. The alcohol intake refers to the amount consumed (gr/day) 
before admission to the ALT Unit.
Total sample MET NULL
Samples size (no.) 160 58 102
Age (yrs.) 44 (SD: 11) 45 (SD: 11) 44 (SD: 12)
Gender
Males 184 51 83
Females 26 7 19
FH for Alcohol Dependence*
Negative 55 17 38
Positive 105 (71%) 41 (63%) 64 (64%)
Alcohol intake prior to admission to the ALT Unit** 189 (SD:62) 175 (SD: 70) 201 (SD: 82)
Age of onset of Alcohol Dependence 27 (SD:11) 26 (SD:10) 27 (SD:12)
(*) Note: FH refers to Family History.
(**) Note: The intake is calculated in grams of alcohol according to Italian standards (see Guerrini et al., 2006 as a reference).Substance Abuse Treatment, Prevention, and Policy 2006, 1:35 http://www.substanceabusepolicy.com/content/1/1/35
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ing disorder by definition. In fact, in the literature it is
quite well known that the first three months of treatment
are very critical in terms of relapsing into drinking and
dropping out from services. It is important to consider this
phenomenon when planning treatment policy and there-
fore the early introduction of relapse prevention meas-
ures, both psychological and pharmacological, becomes
an essential part of the treatment.
Despite all the limitations of our study (small sample size
and non randomisation) the findings support the use of
metadoxine in the management of alcohol dependence.
Our study raises the necessity to investigate the long-term
efficacy of metadoxine in prospective, randomized, con-
trolled trials in large samples.
Methods
We included in the study 160 alcoholics admitted to the
Alcohol misuse Long-term Treatment (ALT) Unit at the
Institute of Psychiatry University of Pisa (Italy) in a period
of a year. All the patients were discharged by different
detoxification units after 15–20 days of treatment and
admitted to the ALT Unit in order to start a long-term
treatment program, which included psychiatric counsel-
ling, self-help group therapy (Club of Alcoholics in Treat-
ment) and pharmacological treatment. We analyzed the
clinical data, psychometric tests and blood tests at the
admission in the ALT Unit and after three months of reha-
bilitative treatment.
Fifty eight alcoholics were in treatment with metadoxine
(MET) as an adjunct to the rehabilitative interventions
and 102 patients (NULL) were drugs free. The assignment
to the metadoxine treatment was not randomised but was
left to the clinical judgement at admission in the ALT
Unit.
The patients included in the study were all Alcohol
Dependent according to DSM III-R criteria and without
any severe medical conditions. At admission in the ALT
Unit the patients received a baseline evaluation that
included: psychiatric interview, blood tests and psycho-
metric rating scales specific for Alcohol Dependence
(Munich Alcoholism Test 1 and 2; Michigan Alcoholism
Screening Test) and for anxiety and depression (Hamilton
Rating Scale for Anxiety- HRSA and for Depression-
HRSD). According to the therapeutic protocol of the ALT
Unit after three months of treatment all the patients were
clinically re-evaluated, the blood tests were repeated and
the rating scales were administered again. The psychomet-
ric rating scales were used in order to evaluate changing in
the drinking habits and in the depressive and anxiety
symptoms induced by the alcohol misuse. All the scales
used in the present studies were validated in different pop-
ulations and used in several studies [27,28]. At this stage
the first evaluation of the treatment outcome was carried
out. Several parameters were taken into account: 1) alco-
hol intake was estimated according to the patients self-
reporting, the weekly report of the self-help groups and
interviewing close relatives; 2) number of relapses; 3)
length of the period of complete abstinence between two
consecutive relapses; 4) drop-out rate.
Statistics
To maximise precision of estimates, analysis of covariance
(ANCOVA) was performed on the rating scales scores and
on the blood tests at baseline and at three months of treat-
ment, using the follow-up data as the dependent measure,
the different treatment group as the independent factor
Table 4: Clinical outcome of the patients recruited in the study at three months follow-up.
MET NULL Chi2 analysis
No. patients 58 102
Drop-outs 10 59 23.22, df = 1; p < 0.0001
Complete abstinence 26 22 8.45, df = 1; p < 0.0037
Table 3: Mean values of the rating scales according to treatment and time points and ANCOVA p-values. SD = Standard Deviation.
MET NULL ANCOVA analysis(*)
Baseline Follow-up Baseline Follow-up
γ GT 290 (SD:386) 165 (SD:56) 190 (SD:309) 71 (SD:74) P < 0.77
GOT 71 (SD:75) 37 (SD:21) 51 (SD:39) 38 (SD:21) P < 0.53
GPT 62 (SD:72) 32 (SD:25) 44 (SD:40) 44 (SD:26) P < 0.54
MCV 97 (SD:10) 92 (SD:7) 97 (SD:8) 96 (SD:8) P < 0.89
(*) Note: p-values are from an F-test with 1, 9 df.Substance Abuse Treatment, Prevention, and Policy 2006, 1:35 http://www.substanceabusepolicy.com/content/1/1/35
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and the baseline data as the covariate. The outcomes ana-
lysed were the number of dropouts and the complete
abstinence rate calculated as the number of individuals
who completely abstain for all the three months period.
The statistical comparison was carried out using a chi
square test with 1 degree of freedom. Statistical analysis
was performed using the SPSS/PC+ package.
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